Idenix Pharma Buyout Likely: Survey
ISI Group biotech analyst Mark Schoenebaum held a lunch meeting Friday for 120 investors to discuss the current state of hepatitis C drug development. As part of his meeting, Schoenebaum surveyed his investor audience -- made up of 30% generalists, 20% arbs and 30% specialists -- on their views and opinions about the current red-hot topics in hepatitis C.
Asked if Idenix Pharma has a greater than 50% chance of being acquired, 79% of the investors responded in the affirmative, 21% said no.
The group was more evenly split on Achillion Pharmaceuticals' (ACHN) chances for a takeout, with 49% leaning yes and 51% saying no.Gilead Science's (GILD) $11 billion acquisition of Pharmasset was the spark that ignited the recent run in Hep C drug stocks. Schoenebaum's buy-side investor crowd likes the blockbuster deal, with 64% predicting Gilead will create value with its purchase of Pharmasset. Thirty-six percent say Gilead is going to destroy shareholder value with this deal. On a related note, 61% say Gilead shares are a buy today. [Gilead shares rose 3 cents to $47.24 Friday and the stock is up about 16% for the year, leading all of the large-cap biotechs.] Thirty-nine percent of Schoenebaum's respondents say Gilead is a sell at these levels. Bristol-Myer Squibb's (BMY) $2.5 billion purchase of Inhibitex (INHX) is also viewed favorably by a wide margin, although a small majority (54%) of investors view Bristol as a sell at current valuation. The size of the commercial opportunity for new all-oral Hep C treatment regimens is a much-debated topic these days. The investors at today's meeting generally fall into the bull camp, with 48% predicting worldwide Hep C drug sales between $8 billion and $10 billion by 2019. Idenix shares neared Friday's close down 6% to $13.94 while Achillion was off 11.5% to $9.39. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV